Data / Drug companies / Devatis, Inc.
Devatis, Inc.: 30 products in the FDA NDC directory, labeler code 73043
Devatis, Inc. (labeler code 73043) lists 30 products in the FDA National Drug Code Directory, covering 13 finished drugs by generic name. By type: 30 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 15, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 73043
- Products in commercial distribution
- 30
- Packages
- 53
- Finished drugs by generic name
- 13
- Prescription products
- 30
- Over the counter products
- 0
- Flagged as original packager
- 29 of 29 products that carry the flag
- Started marketing in the last 12 months
- 8
- Earliest marketing start
- April 28, 2017
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 30 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 30 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 12 | 40% |
| Injection, solution | 6 | 20% |
| Powder, for suspension | 3 | 10% |
| Solution | 2 | 6.7% |
| Tablet, film coated | 2 | 6.7% |
| Injection | 2 | 6.7% |
| Emulsion | 1 | 3.3% |
| Injection, powder, for solution | 1 | 3.3% |
| Solution/ drops | 1 | 3.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Brimonidine Tartrate and Timolol maleate Ophthalmic Solution | 73043-029 | Solution/ drops | Generic drugs (ANDA) | September 15, 2026 |
| Isosulfan Blue | 73043-093 | Injection, solution | Generic drugs (ANDA) | June 30, 2026 |
| Lenalidomide | 73043-043 | Capsule | Generic drugs (ANDA) | January 31, 2026 |
| Lenalidomide | 73043-042 | Capsule | Generic drugs (ANDA) | January 31, 2026 |
| Lenalidomide | 73043-041 | Capsule | Generic drugs (ANDA) | January 31, 2026 |
| Lenalidomide | 73043-040 | Capsule | Generic drugs (ANDA) | January 31, 2026 |
| Lenalidomide | 73043-039 | Capsule | Generic drugs (ANDA) | January 31, 2026 |
| Lenalidomide | 73043-038 | Capsule | Generic drugs (ANDA) | January 31, 2026 |
| Levocarnitine | 73043-034 | Injection, solution | Generic drugs (ANDA) | November 1, 2025 |
| Arformoterol Tartrate Inhalation | 73043-052 | Solution | Generic drugs (ANDA) | August 1, 2025 |
| Pantoprazole Sodium | 73043-020 | Injection, powder, for solution | Generic drugs (ANDA) | August 1, 2025 |
| Formoterol fumarate | 73043-051 | Solution | Generic drugs (ANDA) | June 30, 2025 |
| Chlorpromazine hydrochloride | 73043-049 | Injection | Generic drugs (ANDA) | November 1, 2024 |
| Chlorpromazine hydrochloride | 73043-048 | Injection | Generic drugs (ANDA) | November 1, 2024 |
| Amoxicillin and Clavulanate Potassium | 73043-009 | Powder, for suspension | Generic drugs (ANDA) | November 1, 2024 |
| Amoxicillin and Clavulanate Potassium | 73043-008 | Powder, for suspension | Generic drugs (ANDA) | November 1, 2024 |
| Amoxicillin and Clavulanate Potassium | 73043-007 | Tablet, film coated | Generic drugs (ANDA) | November 1, 2024 |
| Amoxicillin and Clavulanate Potassium | 73043-006 | Tablet, film coated | Generic drugs (ANDA) | November 1, 2024 |
| Succinylcholine Chloride | 73043-021 | Injection, solution | Generic drugs (ANDA) | September 15, 2024 |
| Furosemide | 73043-024 | Injection, solution | Generic drugs (ANDA) | August 10, 2024 |
| Furosemide | 73043-023 | Injection, solution | Generic drugs (ANDA) | August 10, 2024 |
| Furosemide | 73043-022 | Injection, solution | Generic drugs (ANDA) | August 10, 2024 |
| Amoxicillin and clavulanate potassium | 73043-010 | Powder, for suspension | Generic drugs (ANDA) | July 5, 2024 |
| Cyclosporine | 73043-005 | Emulsion | Generic drugs (ANDA) | July 4, 2024 |
| Temozolomide | 73043-016 | Capsule | Generic drugs (ANDA) | April 28, 2017 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.